Imugene gets OGTR tick for poultry booster
01 February, 2006 by Graeme O'NeillLivestock vaccine developer Imugene's (ASX:IMU) chicken immune-system booster has crossed a major intersection on the road to market by receiving approval from the Office of the Gene Technology Regulator to trial its genetically modified product outside full laboratory containment.
Metabolic says obesity drug has potential in osteoporosis
01 February, 2006 by Ruth BeranMetabolic Pharmaceuticals' (ASX:MBP) obesity drug AOD9604 could potentially have a new indication for use in osteoporosis, the company has claimed.
Ventracor implants fifth heart device in US
31 January, 2006 by Helen SchullerArtificial heart company Ventracor (ASX:VCR) has implanted its fifth VentrAssist left ventricular assist system (LVAS) in the United States.
US deal to test Biosignal compounds in catheters
30 January, 2006 by Ruth BeranSydney-based Biosignal (ASX:BOS) and the Institute for Eye Research have established a collaboration with a US-based medical device company to test Biosignal's anti-biofilm compounds coated on catheters.
AtCor Medical boasts sales, revenue growth
30 January, 2006 by Helen SchullerAtCor Medical (ASX:ACG), the developer and marketer of SphygmoCor, a system to measure central cardiovascular function non-invasively, today announced sales of $1.73 million for the six months to 31 December 2005, up 40 per cent compared to the previous corresponding period
Russia recommends approval of Solagran liver disease drug
27 January, 2006 by Helen SchullerThe Russian Ministry of Health has recommended the approval of Melbourne-based Solagran's (ASX:SLA) Ropren, the finished form of Bioeffective R, as a treatment for chronic liver disease.
Mimotopes and Genzyme Pharmaceuticals to collaborate
27 January, 2006 by Ruth BeranPharmAust's (ASX:PAA) subsidiary Mimotopes and US-based Genzyme Corporation have signed a strategic alliance agreement to provide a total suite of peptide products and services to both companies' customer bases.
PolyNovo in $11m deal with Medtronic
25 January, 2006 by Helen SchullerPolyNovo Biomaterials, jointly owned by CSIRO and Xceed Biotechnology (ASX:XBL) has signed a partnering and licensing agreement potentially worth more than AUD$11 million with giant US-based device maker Medtronic.
Epitan opts for name change
25 January, 2006 by Ruth BeranMelbourne-based Epitan (ASX:EPT) is planning to change its name to Clinuvel Pharmaceuticals.
New Peptech CEO excited by Australian opportunities
25 January, 2006 by Graeme O'NeillJohn Chiplin, the new CEO of Sydney biopharma Peptech (ASX:PTD), sees strong similarities between the state of Australia's biotechnology industry and California's nascent biotechnology industry in San Diego in the mid-1980s.
BioProspect raises $1.2m
24 January, 2006 by Ruth BeranNatural pesticide developer BioProspect (ASX:BPO) has raised AUD$1.2 million from its fully underwritten rights offer, where shareholders could subscribe for one new share, at a price of $0.02, and a free attaching option for every three shares held.
CathRx pleased by positive catheter trial results
24 January, 2006 by Ruth BeranA clinical trial conducted by Sydney medical device company CathRx (ASX:CXD) has shown that its catheters can appropriately diagnose arrythmias when measuring electrical signals generated by the heart.
Phosphagenics initiates anti-cancer compound animal trials
24 January, 2006 by Helen SchullerMelbourne's Phosphagenics (ASX:POH, AIM:PSG) will commence animal studies later this month on its patented anti-cancer compound.
Metabolic CEO keen to prove worth of lead drugs
24 January, 2006 by Graeme O'NeillMetabolic Pharmaceuticals (ASX:MBP) CEO Dr Roland Scollay is feeling no pain as his Melbourne-based biopharmaceutical company heads into a potentially momentous year in the clinic for its two lead compounds, the anti-obesity drug AOD9604 and chronic neuropathic pain lead ACV1.
Narhex boss sets out path to market
24 January, 2006 by Helen SchullerSydney-based Narhex has begun recruiting for an early-stage trial of an HIV drug. Helen Schuller spoke with the company's MD, John Mills, about HIV drug development, working in China, and good management.
